hypertrophic cardiomyopathy Archives -

Bristol-Myers Squibb is going after a second indication for its first-to-market cardiac myosin inhibitor Camzyos, a drug tipped

BMS lines up follow-up indication for cardiomyopathy drug Camzyos

https://pharmaphorum.com/news/bms-lines-up-follow-up-indication-for-cardiomyopathy-drug-camzyos/

Bristol-Myers Squibb’s has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming

BMS bags FDA okay for cardiomyopathy drug mavacamten

https://pharmaphorum.com/news/bms-bags-fda-okay-for-cardiomyopathy-drug-mavacamten/

Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it

BMS builds case for mavacamten label ahead of FDA decision

https://pharmaphorum.com/news/bms-builds-case-for-mavacamten-label-ahead-of-fda-decision/

Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM)

Look out BMS, Cytokinetics has its eye on mavacamten’s turf

https://pharmaphorum.com/news/look-out-bms-cytokinetics-has-its-eye-on-mavacamtens-turf/

hypertrophic cardiomyopathy